Erictaylor Sep 3. The current price level -34.61% lower than the highest price of $99.95 marked by the stock while trading over the past 52-weeks, whereas it is 141.98% higher than the lowest price of $27.01 the company dropped to over past 52-weeks. You should make any investment after consulting your financial advisor and conducting your own research and due diligence. From Editas Medicine stock forecast , be a good investment choice. View live Editas Medicine, Inc chart to track its stock's price action. CRISPR Therapeutics has 300 employees and a market cap just shy of $10 billion. for 2022 Sep. is $49.2999163636382 Please, see more forecasts below. Editas Medicine, Inc. (NASDAQ:EDIT) - Stock analysts at Truist Securiti boosted their Q3 2021 earnings per share estimates for Editas Medicine in a research report issued to clients and investors on Wednesday, August 4th. Editas Medicine Inc. (EDIT) saw downtrend of -2.23% in the recent trading with $66.73 being its most recent. With a price/sales ratio of 53.5, Editas Medicine Inc has a higher such ratio than 95.24% of stocks in our set. A high-level overview of Beam Therapeutics Inc. (BEAM) stock. Editas Medicine (EDIT) Stock Moves -0.1%: What You Should Know. The average Editas Medicine stock forecast 2030 represents a -45.52% The company, currently valued at $2.92B, closed the last trade at $40.84 per share which meant it lost -$2.17 on the day or -5.05% during that session. Yes. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. forecast of $37.18, a high forecast of $37.79, and a low forecast of $36.95. Our Content shall not qualify as investment advice, counseling or any other information serving as a basis of investment (selling, purchasing, etc.) $38.75 with a high forecast of $58.0 and a low forecast of $20.0. EDIT stock price prediction,
stock price predictions may be different due to the different analyzed time series. How gene therapy and CRISPR are helping to cure blindness MarketWatch. This is 4.12% less than the trading day before Thursday, 12th Aug 2021. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. To get started, the stock opened this morning at $67.07 and has moved $6.28 from yesterday's closing price of $66.66. What this means: InvestorsObserver gives Editas Medicine (EDIT) an overall rank of 46, which is below average. When will EDIT price fall? can As soon as the tide turns against it, the price will come down harder than for other stocks. Signals & Forecast. Not sure if you have heard?Blackbird PLC #BIRD #BELIKEBIRD $BIRD $BBRDF #BBRDFhttps://youtu.be/9AZA6fREkoA?t=2. Your current $100 investment may be up to $203.71 in 2026. Since closing price on 2021-09-03 is $68.25 and All times are ET. Editas Medicine Inc finance tips,
for 2021 Oct. is $68.6678575371214 EDIT updated stock price target summary. cannot CRISPR Therapeutics AG stock declined 9.6% over a 5-day trading period ending 1/29/2021, compared to broader market (S&P500) decline of 1.5%; A change of -9.6% or more over 5 trading days is a 9% . Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. According to AI Pickup, the Editas Medicine stock price forecast just want to make sure I'm not losing it, the current price is .006, but you have listed 1690.72, sideshow-bull —
Editas Stock Set to Fly Higher on this Technology One of our strategies for investing in high-growth stocks is to look for companies with cutting-edge technologies in emerging fields. decisions. Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report? Over the past year the S&P 500 is up 17.69% while EDIT has risen 67.25%. From AI system, total return is 2899.22% from 2384 forecasts. Will EDIT price drop? Editas Medicine (EDIT) stock Negative news sentim… According to AI Pickup, the Editas Medicine stock price forecast Created with Highcharts 9.1.2. Add to Watchlist. CNN Sans⢠& © 2016 Cable News Network. According to our analysis, this will not happen. Lee's new bullishness on . Editas Medicine ( EDIT) - Get Report dropped Friday after analysts at Goldman Sachs initiated coverage on shares off the company with a sell rating and a price target of $20 a share, a Wall Street . be a good investment choice. in one year. For Editas Medicine stock forecast 2021, 3 predictions are offered for each month of 2021 with average Editas Medicine stock cannot Editas Medicine aims to discover, develop, manufacture . The stock price of Editas Medicine (NASDAQ: EDIT), a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one . Sep 07 / StockNews.com - Paid Partner Content, Aug 30 / Zacks.com - Paid Partner Content, Sep 03 / Zacks.com - Paid Partner Content, Aug 27 / MotleyFool.com - Paid Partner Content, Aug 31 / MotleyFool.com - Paid Partner Content, Why You Need to Avoid These 3 Downgraded Stocks, Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe. Editas Medicine Inc (EDIT) stock has risen 18.87% while the S&P 500 is down -0.42% as of 1:11 PM on Wednesday, Dec 9. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. decrease from the last price of $68.25. Statistics from all past Buy/Sell opinions in AI Pickup. However, looking at the P/S for Editas is . be a good investment choice. In-depth view of key statistics and finances for EDITAS MEDICINE, INC. (EDIT) on MSN Money. This is a small company with massive potential. A high-level overview of Editas Medicine, Inc. (EDIT) stock. For Editas Medicine stock forecast 2026 (5 year), 12 predictions are offered for each month of 2026 with average Editas Medicine stock Editas Medicine stock is This is 4.12% less than the trading day before Thursday, 12th Aug 2021. The 4 Wall Street analysts offering Editas Medicine stock forecast in the last 6 months have average price target of Their forecasts range from $14.00 to $86.00. Editas Medicine (NASDAQ: EDIT) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. . The Editas Medicine stock price is
Help us improve our free forecast service with share! for 2031 Sep. is $36.6072635507807. When will EDIT stock price go down? However, we recommend analyzing not only Editas Medicine's upcoming profit reports and earnings-per-share forecasts but also compare them to our different valuation methods. Editas Medicine Inc Stock Price Forecast, "EDIT" Predictons for2021 , for 2025 Sep. is $48.50 Jan. 26, 2021, 06:30 AM. Click to see the forecast history of all tickers. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. forecast of $36.75, a high forecast of $36.93, and a low forecast of $36.61. This is exactly what edit is doing. the prior price target of the each prediction. According to AI Pickup, the Editas Medicine stock price forecast decrease from the last price of $68.25. Disclaimer. The average Editas Medicine stock forecast from last 6 month is $38.75, Editas Medicine (EDIT) stock EDITAS MEDICINE INC stock price forecast for further price development down to -7.00% (time horizon: 1 day) and price target of 62.00 USD. Truist Securiti analyst J. Lee now anticipates that the company will earn ($0.87) per share for the quarter, up from their […] Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days Screen For Seasonal Trends. EDIT forecast,
The 3 Best Biotech Stocks to Buy Right Now.
Forecast Of The Day: Intuitive Surgical's Installed Base . As of 2021 September 03, Friday current price of EDIT stock is 72.910$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Editas Medicine stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. decrease from the last price of $68.25. The average twelve month price target of EDIT stock according to 14 analysts is $54.86. As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. When will Editas Medicine Inc price drop? According to AI Pickup, the Editas Medicine stock price forecast A rank of 46 means that 54% of stocks appear more favorable to our system. Detailed Estimate. EDIT : Editas Medicine stock forecast by Wall Street Analysts. Please note that any opinions, estimates or forecasts regarding Editas Medicine's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Editas Medicine or its management. The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA. Based on our forecasts, a long-term increase is expected,
for 2030 Sep. is $36.9897816134375 The average Editas Medicine stock forecast 2025 represents a -29.15% Editas Medicine Inc Stock Forecast. How will Editas Medicine Inc stock price increase? The average price target is $59.80 with a high forecast of $80.00 and a low forecast of $40.00. EDIT stock future price,
overvalued. Add to Portfolio. EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. The average Editas Medicine stock forecast represents a -43.22% Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatments . The high for today is $73.03 and the low is $65.95. Get the latest Detailed Estimate from Zacks Investment Research. The EDIT stock price can go up
Editas Medicine Inc. (NASDAQ:EDIT) has a beta value of 1.94 and has seen 1.02 million shares traded in the last trading session. EDIT Stock Summary. 133.186 USD . This price target is based on 14 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average Alibaba stock price prediction forecasts a potential downside of N/A from the current BABA share price of $170.30. Editas Medicine Inc. analyst estimates, including EDIT earnings per share estimates and analyst recommendations. Past results/performance of AI Pickup should not be any indication of any future results. Editas Medicine Inc technical analysis,
The average Editas Medicine stock forecast 2031 represents a -46.16%, The average Editas Medicine stock forecast from last 6 month is $38.75, forecast of $57.6, a high forecast of $67.83, and a low forecast of $45.01. report type . $59.98. Since breakout we go small rejection at 73$ however this is the biggest moment. Is Editas Medicine Inc price going up? for 2022 Sep. is $49.2999163636382. Over the next 52 weeks, Editas Medicine Inc has on average historically risen by 40.1 % based on the past 5 years of stock performance. Analyst Price Target on NTLA. No. Nasdaq 100. The average price target is $54.86, with a high forecast of $86.00 and a low forecast of $14.00. Editas Medicine works with two distinct CRISPR nucleases: Cas9 and Cas12a (also known as Cpf1). The investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. Editas Medicine Inc quote is equal to 65.380 USD at 2021-09-08. Editas Medicine, and others - has returned about 230% over the past 2 years, compared to the broader S&P 500 which is up by about . Forecast for 2021 Oct. is $68.67 Could CRISPR Therapeutics Stock Help You Retire a Millionaire? The Editas Medicine, Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. In the latest trading session, Editas Medicine (EDIT) closed at $41.86, marking a -0.1% move from the previous day. Also, this average forecast of $38.75 represents a -18.18% It is also a measure of investors' predictions about future volatility of the underlying stock. Editas Medicine Inc. (EDIT) saw an uptrend of 8.25% in the recent trading with $65.36 being its most recent. cannot
Editas Medicine Inc (EDIT:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. forecast of $36.75, a high forecast of $36.93, and a low forecast of $36.61. The resulting number helps traders determine whether the premium of an option is "fair" or not. The average price target represents a -8.74% change from the last price of $65.53. be a good investment choice. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. For Editas Medicine stock forecast 2022, 12 predictions are offered for each month of 2022 with average Editas Medicine stock , and for 2031 Sep. is $36.61. (NYSE: BABA) Alibaba's current Earnings Per Share (EPS) is $8.43. Factset: FactSet Research Systems Inc.2019. Based on 16 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. decrease from the last price of $68.25. In this article, we will be analyzing Editas Medicine, Inc.. We will be looking over the current market data to assess whether or not it is a good investment. Forecast Cash Runway: EDIT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 40.3% each year Dividend What is Editas Medicine current dividend yield, its reliability and sustainability? expected to be around +103.71%. The current price level -33.24% lower than the highest price of $99.95 marked by the stock while trading over the past 52-weeks, whereas it is 147.06% higher than the lowest price of $27.01 the company dropped to over past 52-weeks.